Shaun Chilton – CEO, Clinigen Group, UK
A British success story, Clinigen Group provides companies with services in portfolio and product lifecycle management on a global basis. Its CEO, Shaun Chilton, talks to us about the value…
Address: 6 Henrietta Street
London
WC2E 8PU
Tel: +44 (0)20 7557 7500
Web: http://www.mvmlifescience.com/
Heptares is a drug discovery company creating new medicines targeting G-protein-coupled receptors (GPCRs).
The Company is currently leveraging its GPCR expertise and proprietary StaR® technology to build a pipeline of best-in-class and first-in-class GPCR-targeted medicines for the treatment of CNS, metabolic and other diseases.
Heptares Therapeutics Ltd has already four-year collaboration with AstraZeneca (2011), where they focused on developing small molecule and antibody candidates targeting specific GPCRs linked to CNS/pain, CV/metabolic and inflammatory disorders.
Also, an approximately $100 million drug discovery collaboration with Takeda (2011) focused on a GPCR linked to CNS disorders.
Moreover, $200 million alliance with the Novartis Option Fund (2009) focused on single GPCR target of strategic interest to Novartis. Novartis and Heptares jointly announced the successful first-ever stabilisation of this previously intractable GPCR using the Heptares technology.
Heptares Therapeutics Ltd deploys structure-based drug discovery techniques to identify potent and selective drug candidates to previously undruggable targets. They develop small molecule and antibody candidates targeting specific GPCRs linked to CNS/pain, CV/metabolic and inflammatory disorders.
A British success story, Clinigen Group provides companies with services in portfolio and product lifecycle management on a global basis. Its CEO, Shaun Chilton, talks to us about the value…
Having recently joined the UK operations of AstraZeneca after a varied international career, Laurent Abuaf shares his vision of the UK as a life sciences reference market and his take…
Heading Accord Healthcare’s European, Middle East and North African operations, James Burt highlights the rapid growth the company has achieved within the region and how it has reached an impressive…
Promoting the UK’s capital in times of Brexit, Laura Citron, CEO at London & Partners, the international promotional agency of the Mayor of London, stresses the critical importance life sciences…
Erik Nordkamp, managing director of Pfizer UK, has been confirmed as the new president of the Association of the British Pharmaceutical Industry (ABPI). With UK life sciences still uncertain as…
Craig Wallace established the UK affiliate of Santen, the Japanese ophthalmology company, in 2014. Wallace describes the journey Santen has been on so far in the UK, as well as…
Britain, home of the discovery of the world’s first ever vaccine, has long been championing a pharma sub-segment forecast to reach a global market value of USD 49.27 billion by…
Thomas Bo Bjorn Klee, managing director of Lundbeck UK and Ireland, describes the global restructuring program Lundbeck initiated two years ago to ensure value creation, build on unique strengths and…
Having recently been able to present positive data for their lead technology IMCgp100 in uveal melanoma at the American Society of Clinical Oncology (ASCO), Immunocore looks at its future as…
Erik Nordkamp, managing director of Pfizer UK shares his thoughts on the future of healthcare and the role that Pfizer and the UK can play in shaping it. He explains…
Stewart Pearce, managing director of Otsuka UK and Ireland since 2017 discloses how he built up a leadership team fit for the Otsuka of 2023 and highlights what he appreciates…
As the UK extracts itself from the European Union, key figures from the country’s life sciences sector are split on the implications of Brexit for their industry. “The UK pharmaceutical…
See our Cookie Privacy Policy Here